Cerecor to Present at the 15th Annual BIO
Investor Forum in San Francisco on October 18th, 2016

October 10, 2016 09:10 AM Eastern Daylight Time

BALTIMORE--(BUSINESS WIRE)--Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company
developing treatments to make a difference in the lives of patients with
neurological and psychiatric disorders, today announced it will be
featured as a presenting company at the 15th Annual BIO
Investor Forum. The Forum will be held on October 18th
and 19th at the Westin St. Francis Hotel in San Francisco.

Dr. Uli Hacksell, President and Chief Executive Officer of Cerecor, will
provide an overview of the Company's business during the live
presentation and will be available to participate in one-on-one meetings
with investors who are registered to attend the forum.

Presentation Date:

Tuesday, October 18, 2016

Time:

8:00 am (Pacific Time)

Location:

Elizabethan A Room

The presentation will be webcast live and will be available on the
bio.org website. The webcast will remain available for 90 days following
the live presentation on the Company’s website.

About CerecorCerecor is a clinical-stage
biopharmaceutical company developing innovative drug candidates to make
a difference in the lives of patients with neurological and psychiatric
disorders. Cerecor is currently pursuing the development of two clinical
Phase 2-stage product candidates, CERC-301 and CERC-501; as well as two
earlier stage programs.

CERC-301 is an oral, NR2B specific N-methyl-D-aspartate receptor
antagonist that is currently in a Phase 2 clinical trial as an oral,
rapidly acting adjunctive treatment for patients with severe major
depressive disorder (“MDD”) who are failing to achieve an adequate
response to their current antidepressant treatment. We expect top-line
data from this trial in November 2016. Cerecor received fast track
designation by the United States Food and Drug Administration in 2013
for CERC-301 for the treatment of MDD. We believe CERC-301 has the
potential to be a first-in-class medication that may significantly
reduce depressive symptoms in a matter of days.

CERC-501 is a potent and selective kappa opioid receptor antagonist that
is currently in a Phase 2 clinical trial for smoking cessation that is
expected to provide top-line data in December 2016. In addition to
Cerecor’s Phase 2 trial, three externally-funded clinical trials are
being conducted to evaluate the use of CERC-501 in treating depressive
symptoms, stress related smoking relapse and cocaine addiction. One
study is being conducted under the auspices of the National Institute of
Mental Health, the second is a collaboration between Cerecor and Yale
University with funding from the National Institutes of Health and the
third is being conducted at Rockefeller University Hospital with funding
from a private foundation.

CERC-611 is a potent and selective Transmembrane AMPA Receptor
Regulatory Proteins-γ8-dependent AMPA receptor antagonist in development
as an adjunctive therapy for the treatment of partial-onset seizures
with or without secondarily generalized seizures in patients with
epilepsy. CERC-611 was recently acquired from Eli Lilly and we expect to
file an IND and commence Phase 1 development in 2017.

Cerecor’s brain penetrant catechol-O-methyltransferase inhibitors,
including CERC-406, are in preclinical development and may have
potential procognitive activity.

For more information about the Company and its products, please visit www.cerecor.com or
contact Mariam E. Morris, Chief Financial Officer, at (443) 304-8002.